Today’s episode dives into the pressing issue of historical inaccuracies in AI-generated images, leading to Google pausing its AI tool, Gemini. This essential story underlines the critical need for ethical considerations and rigorous testing in AI development. Additionally, we explore Pfizer’s launch of ‘Charlie,’ a new generative AI platform for pharmaceutical marketing, showcasing the expanding role of AI in highly regulated industries. While Microsoft makes headlines by releasing its internal generative AI red teaming tool to the public, aimed at enhancing AI security and reliability. We also touch upon the latest developments in AI technologies, including Stable Diffusion 3 and ChatGrid, though these stories carry a more optional weight for our viewers.
Timestamps:
0:30 Google Pauses Gemini Due to Historical Inaccuracies
5:00 Pfizer’s AI Platform ‘Charlie’ for Pharma Marketing
10:00 Microsoft’s Public Release of AI Red Teaming Tool
15:00 Overview of Stable Diffusion 3
20:00 ChatGrid: Power Grid Visualization with AI
25:00 The Justice Department Welcomes Chief AI Officer
Key Highlights:
– The significance of ethical AI development and the challenges it faces.
– The role of AI in transforming pharmaceutical marketing strategies.
– The importance of AI security and the tools enhancing it.
– Innovations in AI technology and their specific applications.
Don’t forget to like, subscribe, and hit the bell icon to stay updated on the latest in AI.
Join us every weekday LIVE at 7:30 AM ET on LinkedIn or YouTube for comprehensive discussions on AI.
https://www.linkedin.com/company/gai-insights/
Share your thoughts and questions in the comments section below or join our live discussions. Your insights enrich our community’s understanding and appreciation of the evolving AI landscape.
Our analysts: Paul Baier, John Sviokla, Tim Andrews, David De Lallo, Tania DiCostanzo, Amanda Fetch, Luda Kopeikina, and Adam Rappaport
Add comment